Seeking Alpha
 

CVS Health Corporation (CVS)

- NYSE
  • Aug. 7, 2012, 7:25 AM
    More on CVS Caremark (CVS): Pharmacy Services sales up 28.2% Y/Y to $18.4B, led by new client starts and drug cost inflation. Retail Pharmacy 6.9% higher to $15.8B, with Walgreen-Express Scripts dispute impacting results. Raises and narrows full-year EPS to $3.32-$3.38, up from prior guidance of $3.23-$3.33. (PR)
    | Comment!
  • Aug. 7, 2012, 7:07 AM
    CVS Caremark (CVS): Q2 EPS of $0.81 beats by $0.02. Revenue of $30.7B misses by $270M
    | 5 Comments
  • Aug. 7, 2012, 12:05 AM
    Notable earnings before Tuesday’s open: AKRX, AMRC, APU, ARCC, ARCO, BPI, CHD, CRZO, CVC, CVS, DWRE, EBIX, EMR, ENDP, EXPD, FE, FOSL, GTE, HL, HPT, KITD, KWK, MEA, MGM, MMC, MNKD, MPEL, NIHD, ODP, PCG, POM, SIRI, SOL, STWD, TAP, THC, TIE
    | Comment!
  • Aug. 6, 2012, 5:30 PM
    Notable earnings before Tuesday’s open: AKRX, AMRC, APU, ARCC, ARCO, BPI, CHD, CRZO, CVC, CVS, DWRE, EBIX, EMR, ENDP, EXPD, FE, FOSL, GTE, HL, HPT, KITD, KWK, MEA, MGM, MMC, MNKD, MPEL, NIHD, ODP, PCG, POM, SIRI, SOL, STWD, TAP, THC, TIE
    | 1 Comment
  • Aug. 3, 2012, 1:00 PM
    CVS Caremark (CVS -0.9%) trades lower after Cleveland Research warns that the number of accounts that it loses back to Walgreen from returning customers may be even more than the 50% it forecast earlier this month. Promotional activity and advertising from Walgreen may be contributing to the extra pharmacy account losses.
    | 1 Comment
  • Jul. 19, 2012, 10:35 AM
    CVS Caremark (CVS -4.4%) weighs in on the impact of the new Walgreen-Express Scripts agreement. The drugstore operator adds $0.05 to its overall FY12 estimate of extra business from the WAG-ESRX dispute after factoring in that it will retain 50% of the customers it gained from Walgreen through Q4.
    | Comment!
  • Jul. 19, 2012, 9:10 AM
    Premarket gainers: MLNX +42%. SCSS +21%. GGC +16%. NOK +13%. WAG +11%. SWKS +10%. TXT +9%. EDU +8%. EBAY +8%. ALU +7%. QCOM +6%. PPG +5%. LUV +5%.
    Losers: ANTH -15%. DCIX -15%. JCI -8%. CVS -6%.
    | Comment!
  • Jul. 19, 2012, 8:17 AM
    Shares of CVS Caremark (CVS) fall off 7.9% premarket after Walgreen and Express Scripts hash out a new pharmacy network agreement. The company had been one of the biggest beneficiaries of the WAG-ESRX dispute.
    | 1 Comment
  • Jul. 17, 2012, 6:54 AM
    JMP Securities resumes coverage on CVS Caremark (CVS) with an Outperform rating. Analysts set a $55 price target on shares, repping 16% upside potential for shares. The company has also seen a pickup in insider buying this month.
    | Comment!
  • Jul. 11, 2012, 1:29 PM
    CVS Caremark (CVS -0.2%) looks like a good defensive long-term play, according to Stephanie Link. She likes management's focus on quality of contracts over pricing and sees a continual grab of market share from Walgreen. If the WAG-ESRX continues to the end of the year, factor in another $0.02-$0.03 to the bottom line of CVS.
    | 2 Comments
  • Jul. 5, 2012, 1:54 PM
    CVS Caremark (CVS) dividend alert: Declares $0.1625/share quarterly dividend, in line with previous. Dividend yield 1.3%. For shareholders of record July 23; payable Aug 03; ex-div date July 19. (PR)
    | Comment!
  • Jun. 28, 2012, 1:39 PM
    While the Supreme Court opinion on healthcare is being called a drag on the retail sector by industry insiders, especially so for high-growth stories such as Chipotle (CMG -4.6%), Starbucks (SBUX -2.1%), and Dunkin' Brands (DNKN -3.2%), NBG's Brian Sozzi suggests a way to trade the news. He throws out WAG, CVS, and TGT as retail names that already have their employee structure in place and could be good long-term plays under the current retail environment.
    | 5 Comments
  • May 25, 2012, 8:00 AM
    Wal-Mart (WMT) says it's seeing good results with a pilot program of small-sized stores called Walmart Express. Execs say the stores are showing profits and the company could roll out hundreds more in the near future. Designed to catch spur-of-the-moment shoppers and small enough to tuck into tight spaces, Walmart Express stores could pose a threat to Walgreen (WAG), CVS Caremark (CVS), and Rite Aid (RAD) in the future.
    | 10 Comments
  • May 2, 2012, 12:38 PM
    Walgreen's (WAG -0.9%) pain is CVS Caremark's (CVS +2.1%) gain, according to the tale told by the two earnings reports (I, II) from the firms. Though a mild flu season struck the bottom line of both drugstore operators, CVS says it saw a "significant benefit" from customers pounding the pavement for its doors from Walgreen over the dispute with Express Scripts. CVS +12.0% YTD vs. WAG +3.9%.
    | Comment!
  • May 2, 2012, 7:27 AM
    More on CVS Caremark's (CVS) Q1: Retail Pharmacy segment same stores sales increased 8.4%. Pharmacy Services revenue +32.3% Y/Y to $18.3B. Retail Pharmacy +9.9% Y/Y to $16.0B. Generated free cash flow of $2.4B. Expects Retail Pharmacy operating profit to increase 10.5%-12.5%, up from a prior estimate of 8.5%-10.5%. Increases full EPS guidance to $3.23-$3.33, from $3.18-$3.28. Shares +1.5% premarket. (PR)
    | Comment!
  • May 2, 2012, 7:15 AM
    CVS Caremark (CVS): Q1 EPS of $0.65 beats by $0.02. Revenue of $30.8B (+19.9% Y/Y) beats by $500M. (PR)
    | Comment!
Visit Seeking Alpha's
CVS vs. ETF Alternatives
Company Description
CVS Health Corp iis an integrated pharmacy health care provider. The Company has three segments: Pharmacy Services, Retail Pharmacy and Corporate.
Sector: Healthcare
Industry: Drug Stores
Country: United States